Are gabapentin and hydroxyzine nephrotoxic?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Are Gabapentin and Hydroxyzine Nephrotoxic?

Gabapentin is not directly nephrotoxic but requires dose adjustment in renal impairment because it is almost exclusively eliminated by the kidneys, and accumulation can cause severe toxicity; hydroxyzine is not nephrotoxic and does not require renal dose adjustment.

Gabapentin and Kidney Function

Renal Elimination, Not Renal Toxicity

Gabapentin is not a nephrotoxic drug in the traditional sense—it does not cause direct tubular injury, interstitial nephritis, or glomerular damage. However, it presents significant safety concerns in patients with kidney disease because it is almost exclusively eliminated by renal excretion 1.

The FDA label explicitly states: "This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function" 1. This is a pharmacokinetic issue, not nephrotoxicity.

Critical Distinction: Accumulation vs. Injury

The KDIGO guidelines 2 clarify that some drugs "lead to kidney dysfunction without direct glomerular or tubular cell damage." Gabapentin falls into this category—it doesn't injure the kidney, but impaired kidney function dramatically prolongs its half-life:

  • Normal renal function: 5-7 hours
  • Advanced CKD: 52-132 hours (a 10- to 20-fold increase) 3

This massive accumulation causes systemic toxicity (encephalopathy, coma, ataxia) rather than kidney injury 4, 5.

Evidence of Gabapentin Effects on Renal Function

One isolated case report 6 from 2000 described reversible acute renal dysfunction in a transplant recipient, hypothesizing renal afferent vasoconstriction. However, this single case has not been replicated in 25 years of subsequent literature.

More concerning is recent comparative data 7: In a 2024 target trial emulation study of 640 matched pairs, perioperative gabapentin initiation was associated with higher risk of kidney function decline (HR 1.40,95% CI 1.04-1.89) and incident CKD (HR 1.46,95% CI 1.03-2.05) compared to pregabalin. This suggests gabapentin may have subtle effects on renal function beyond simple accumulation, though the mechanism remains unclear.

Clinical Management Algorithm

For patients with normal renal function:

  • Standard dosing is safe
  • No nephrotoxicity monitoring required

For patients with CKD (eGFR <90 mL/min/1.73m²):

  • Mandatory dose reduction based on creatinine clearance 1
  • High risk of neurotoxicity even at low doses (≤300 mg) 3
  • Consider pregabalin as alternative (4-fold vs. 10-20-fold half-life extension) 3
  • Monitor for encephalopathy, ataxia, confusion 4

For dialysis patients:

  • Supplemental dosing after each dialysis session required 1
  • Extremely high toxicity risk (77.8% in one series) 4
  • Gabapentin is dialyzable 5

Common Pitfall

Toxicity is frequently missed: In one study of 729 patients, gabapentin toxicity was initially suspected in only 41.5% of symptomatic cases 4. Elderly patients with multiple comorbidities are particularly vulnerable and often receive inappropriately high doses for their kidney function 4.

Hydroxyzine and Kidney Function

Hydroxyzine is not nephrotoxic and does not require renal dose adjustment. It undergoes hepatic metabolism, not renal elimination.

In the only comparative study identified 8, 32 dialysis patients received hydroxyzine 25 mg/day for 6 weeks with no reported renal adverse effects. Both hydroxyzine and gabapentin effectively reduced pruritus in this population, but the study focused on efficacy rather than safety outcomes.

The KDIGO framework 2 for drug-associated kidney injury does not list hydroxyzine among agents causing hemodynamic effects or structural damage. No FDA warnings exist regarding renal toxicity.

Clinical Bottom Line for Hydroxyzine

  • Safe in all stages of CKD
  • No dose adjustment needed
  • May cause sedation (monitor in elderly)
  • Reasonable alternative to gabapentin for pruritus in dialysis patients 8

Key Takeaway

Gabapentin is renally eliminated but not nephrotoxic—it accumulates dangerously in kidney disease causing neurotoxicity, and emerging evidence suggests it may accelerate kidney function decline compared to pregabalin. Hydroxyzine is neither nephrotoxic nor renally eliminated and requires no special precautions in kidney disease beyond standard monitoring for sedation.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.